Sun Pharma to license key Escitalopram patent applications to Lundbeck

News Flash

CRUDE FALLS 2.6% TO $77.43 BBL
COPPER DOWN TO $6490/TON ON WEAK DEMAND AND US UNEMPLOYMENT DATA
Email us at buyorsell@ndtv.com
Call us at 011-26201171
Stock moves on WAP: Logon to mobile.ndtv.com on GPRS browser
SMS INDEX to 56388 for live market updates
Finance buzz: Logon to mobile.ndtv.com on GPRS browsers
Stock updates: SMS STO followed by scrip name to 56388
For Kingfisher Airlines flight updates sms KING to 56388
CO TO LAUNCH ITS 3 SCREENS MULTIPLEX IN KANPUR
DOW JONES UP 0.17%; NASDAQ UP 0.34%; S &P 500 UP 0.25%
RCOM LOSES 0.1%, SHEDS 23.5 LAKH SHARES IN OPEN INTEREST
IDEA LOSES 5.2%, ADDS 30.6 LAKH SHARES IN OPEN INTEREST
ASHOK LEYLAND GAINS 4.9%, ADDS 32.4 LAKH SHARES IN OPEN INTEREST
NIFTY CLOSES JUST BELOW 4800 AFTER A GAP UP OPENING
STRONG AT $1095/OZ AS SAFETY MEASURE POST RISE IN U.S UNEMPLOYMENT DATA
U.S UNEMPLOYMENT DATA AT 26 YEAR HIGH;CRUDE FALLS 2.6% TO $77.43 BBL
SMS BOS < SPACE > MF, MUTUAL FUND QUERY AT 56388
ISSUES REGULATORY FRAMEWORK FOR AUTHORISED PERSONS
AUTHORISED PERSONS CAN FACILITATE TRADING THROUGH BROKER TERMINALS
STOCK BROKERS TO SEEK SEBI APPROVAL FOR APPOINTING AUTHORISED PERSONS
COS GETTING FRESH FDI IN SECTORS WHERE FDI CAPS HAVE GONE UP: SOURCES
NEW NORMS TO CONSIDER TOTAL FOREIGN INVESTMENT NOT TOTAL INVESTMENT: SRCS
CCEA NOD NEEDED ONLY FOR INVESTMENTS OF RS.1200 CR AND ABOVE: SOURCES
GOVT TO EASE NORMS FOR FDI REQUIRING CABINET APPROVAL: SOURCES
NO PLANS TO OFFER HOME LOANS AT 8%: NW
DOMESTIC FUNDS NET BUY RS.236.62 CR IN EQUITIES ON NOVEMBER 6 (PROVISIONAL)
FOREIGN FUNDS NET BUY RS.587.02 CR IN EQUITIES ON NOVEMBER 6 (PROVISIONAL)
EXL TO ACQUIRE BACK-OFFICE OPS OF AXP BUSINESS TRAVEL IN INDIA FOR $30 MN
EXL ENTERS MULTI-YEAR SERVICES PACT WITH AMERICAN EXPRESS

Updated: 11/07/2009 | 12:00 AM IST

Manufacturing

Capital Market

Saturday, July 11, 2009 (New Delhi)

Blog

Comments:

Read (0)

Post

Rate the story

Sun Pharmaceutical Industry has today announced that Caraco Pharmaceutical Laboratories has entered into agreements with Forest Laboratories, Forest Laboratories Holdings and Lundbeck to settle the legal proceedings related to Lexapro (Escitalopram oxalate) tablets.

Sun Pharma will license to Lundbeck on a world wide basis certain patent applications related to the synthesis of escitalopram and citalopram in exchange of an upfront payment and if the technology is used, royalties on sales. Forest will provide licenses to Caraco for any patent related to Lexapro and with respect to marketing of Caraco's generic version of the product as of the date that any third party generic that has recieved final approval from FDA enters the market other than an authorised genericor first filer with Hatch Waxman related exclusivity.

Caraco will take over the commercialization and sale of several products from Forests Inwood business. Caraco will pay forest an undisclosed advance against royalties and royalties on net sales of these products. Forest will reimburse Caraco for a portion of their costs related to this litigation.

These agreements will be subject to review by US Federal Trade Commission.

The company made this announcement after the trading hours on 10 July 2009.